The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice

Ítems similars

• Pre-clinical development of the human CD40 agonistic antibody ADC-1013
  per: Norlén, Per, et al.
  Publicat: (2015)
• ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
  per: Mangsbo, Sara M, et al.
  Publicat: (2013)
• Kick-starting the cancer-immunity cycle by targeting CD40
  per: Ellmark, P, et al.
  Publicat: (2015)
• Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
  per: Ellmark, Peter, et al.
  Publicat: (2016)
• The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
  per: Kvarnhammar, Anne Månsson, et al.
  Publicat: (2019)